ArticleFrontiers in oncology2024
Primary intestinal diffuse large B-cell lymphoma: novel insights and clinical perception.
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- The surgery for the patients with intestinal non‑Hodgkin lymphomas: a nationwide study.Annals of medicine · 2026Article
- Epidemiological and clinical trends of malignant small-bowel tumors in Asia.The Korean journal of internal medicine · 2026Review
- Increased CCR5 expression in lymphoma cells and M2 macrophages is associated with poor prognosis in primary intestinal diffuse large B-cell lymphoma.The journal of pathology. Clinical research · 2026Article
- The Diagnostic Challenge of Crohn's Disease With Initial Duodenal Involvement: Two Cases and Literature Review.Immunity, inflammation and disease · 2026Review
- The Role of Surgery in the Management of Intestinal Diffuse Large B-Cell Lymphoma (DLBCL): A Propensity Score-Matched Analysis.Annals of surgical oncology · 2026Article
- Intestinal T-cell lymphoma not otherwise specified presenting with Jejunal perforation: a case report and review of the literature.Journal of medical case reports · 2026Review
- Anatomical laterality of primary intestinal diffuse large B-cell lymphoma independently stratifies survival: New prognostic nomogram incorporating tumor location.World journal of gastroenterology · 2026Article
- Rectal diffuse large B-cell lymphoma misdiagnosed as bleeding cancer in an elderly patient.Discover oncology · 2026Article
- Case Report: longitudinal immunoglobulin abnormalities preceding IgA-λ MGUS and colonic DLBCL: a case suggesting immune-driven B-cell dysregulation.Frontiers in oncology · 2026Article
- Unmasking small-bowel DLBCL in an elderly patient with simultaneous multiple primary cancers through anemia: a case report and literature review.Frontiers in oncology · 2026Article
- CD5-positive diffuse large B-Cell lymphoma presenting with protein-losing enteropathy.Journal of clinical and experimental hematopathology : JCEH · 2026Article
- Clinical characteristics and prognostic analysis of three hundred and nineteen cases of primary gastrointestinal diffuse large B-cell lymphoma.World journal of gastrointestinal oncology · 2025Article
- Primary High-Grade Diffuse Large B-Cell Lymphoma of the Cecum: A Report of a Rare Case.Cureus · 2025Article
- Primary Gastrointestinal B-Cell Lymphomas: A Clinicopathological Review.Journal of hematology · 2025Review
- Emerging Roles of Fc Receptor-Like 1 in Immunotherapy of Diffuse Large B-Cell Lymphoma.Biocell : official journal of the Sociedades Latinoamericanas de Microscopia Electronica ... et. al · 2025Article
- Clinical Features and Outcomes of Primary Colorectal Diffuse Large B-Cell Lymphoma: A Multicenter Retrospective Study.Cancer medicine · 2025Article
- Location-specific analysis of clinicopathological characteristics and long-term prognosis of primary gastrointestinal diffuse large B-cell lymphoma.Scientific reports · 2025Article
- Gastrointestinal lymphoma in a patient on long-term azathioprine therapy: A case report with imaging features mimicking Crohn's disease.Radiology case reports · 2025Article
- Review
- Diffuse B cell large ileal lymphoma presenting with obstruction and associated with Hashimoto's thyroiditis.Journal of surgical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Extranodal Non-Hodgkin lymphoma (NHL) is more prevalent in the gastrointestinal (GI) tract than in other sites. This study aimed to explore the clinical features and prognostic factors of primary intestinal diffuse large B-cell lymphoma (PI-DLBCL), in order to provide new references for basic research and clinical diagnosis and treatment of the rare extranodal malignant lymphoma. Methods: The clinical data of 88 patients with PI-DLBCL admitted to Fujian Medical University Union Hospital from June 2011 to June 2022 were retrospectively studied, the clinical and pathological features, diagnosis and treatment process and prognosis of PI-DLBCL were analyzed, and univariate and multivariate analysis of prognostic factors was carried out. The Kaplan-Meier method was used for survival analysis. Meanwhile, the latest literature from PubMed was retrieved to systematically discuss the research progress in the diagnosis and treatment of PI-DLBCL. Results: Among the 88 patients with PI-DLBCL included in this study, 60 cases were males (68.18%), 28 cases were females (31.82%), and 62 patients (70.45%) were complaining of abdominal pain, and the second most common clinical manifestation was changes in bowel habits in 16 (18.18%), with a median age of onset of 57 (17-82) years. The first-line treatment regimen was surgery combined with R-CHOP chemotherapy (56.82%). The median follow-up time was 72 (1-148) months, 51 (57.95%) of 88 patients with PI-DLBCL survived, 30 patients (34.09%) died, 7 patients (7.95%) were lost to follow-up, and the PFS rates of 1-year, 3-year and 5-year were 57.95%, 29.55% and 15.91%, and the OS rates of 1-year, 3-year and 5-year were 79.55%, 45.45% and 28.41%, respectively. The results of univariate Conclusion: PI-DLBCL is more common in middle-aged and elderly men, clinical manifestations lack specificity, first-line treatment is mainly surgery combined with standard chemotherapy regimens. The Lugano stage may be an independent prognostic factor affecting OS and PFS in PI-DLBCL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.